On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7$2.75.JNJ is trading at elevated levels. See what the experts say here.Johnson & Johnson also announced plans to separate its Orthopedics business to enhance strategic and operational focus.The transaction would establish a standalone orthopedics business, operating as DePuy Synthes. Johnson & Johnson aims to complete the project within 18 to 24 month ...